Hims & Hers Earnings Disappoint After Q3 Margin Squeeze
Hims & Hers earnings showed 49.0% revenue growth but steep margin compression, a GAAP loss and trimmed 2026 adjusted EBITDA guidance, pressuring shares.
KEY TAKEAWAYS
- Q3 revenue rose 49.0% to $890 million while subscribers reached 2.788 million but fell about 100,000 sequentially.
- Gross margin compressed to 57.0% from 74.0%, producing a GAAP net loss of $33 million.
- Company cut full-year 2026 adjusted EBITDA guidance to $257 million-$277 million, tightening profit visibility.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Hims & Hers Health, Inc. (HIMS) reported on November 9, 2026, strong top-line growth but sharp margin compression, a swing to a GAAP net loss, and a trimmed 2026 adjusted EBITDA outlook, narrowing near-term profitability prospects.
Revenue, Margins and Subscribers
Hims & Hers posted third-quarter 2026 revenue of $890.4 million for the quarter ended September 30, up 49.0% year over year. U.S. revenue rose 21.0% to $657.1 million, while rest-of-world revenue surged 321.0% to $233.3 million, reflecting the impact of the Eucalyptus acquisition.
Gross margin fell sharply to 57.0% from 74.0% a year earlier, weighing on results. The company recorded a GAAP net loss of $33.0 million, compared with net income of $15.8 million in the prior-year quarter. Adjusted EBITDA rose slightly to $82.4 million, producing a margin of about 9.0%, indicating modest underlying profitability relative to revenue.
Subscribers totaled 2.788 million at quarter-end, up 13.0% year over year but down roughly 100,000 sequentially. Management attributed the sequential decline to measured reductions in U.S. weight-loss marketing and brand migrations in international markets, framing it as a deliberate choice rather than a sudden drop in demand.
Guidance, Cash Flow and Deferred Revenue
The company narrowed its full-year 2026 revenue guidance to a range of $3.13 billion to $3.15 billion and reduced adjusted EBITDA guidance to $257 million to $277 million. For the fourth quarter, it projected revenue between $875 million and $895 million and adjusted EBITDA of $70 million to $90 million, implying margins of approximately 8.0% to 10.0%. Management cited planned pricing and marketing investments in the U.K. and Germany as factors influencing the outlook.
Free cash flow declined to $26.0 million from $79.4 million in the year-ago quarter. Management said about $18 million of weight-loss membership revenue was deferred from the third to the fourth quarter but stated this deferral did not affect free cash flow generation.
The results highlight a tradeoff between rapid revenue growth and near-term profitability. Strong top-line expansion coincided with significant margin compression, a GAAP loss, weaker free cash flow, and a lowered adjusted EBITDA outlook, tightening expectations for profit and cash generation in the near term.
